Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Prostate Cancer

Free Subscription 20.05.2019 1 Am J Pathol 3 Anticancer Res 2 BJU Int 1 Br J Cancer 1 Cancer 1 Eur J Radiol 2 Eur Urol 2 Int J Cancer 3 Int J Oncol 1 Int J Radiat Oncol Biol Phys 3 Int J Urol 1 J Magn Reson Imaging 1 J Natl Cancer Inst 4 J Urol 3 N Engl J Med 1 Nat Rev Urol 1 Oncology (Williston Park) 2 PLoS One 2 Proc Natl Acad Sci U S A 3 Prostate 3 Urology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Pathol

1. HWANG MJ, Bryant KG, Seo JH, Liu Q, et al
   Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor.
   Am J Pathol. 2019 May 3. pii: S0002-9440(18)30742.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

2. DUDZIK P, Trojan SE, Ostrowska B, Zemanek G, et al
   The Epigenetic Modifier 5-Aza-2-deoxycytidine Triggers the Expression of CD146 Gene in Prostate Cancer Cells.
   Anticancer Res. 2019;39:2395-2403.
   PubMed     Text format     Abstract available
   
   
3. KADOMOTO S, Yaegashi H, Nakashima K, Iijima M, et al
   Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy.
   Anticancer Res. 2019;39:2553-2559.
   PubMed     Text format     Abstract available
   
   
4. BECKER DJ, Iyengar AD, Punekar SR, Ng J, et al
   Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
   Anticancer Res. 2019;39:2467-2473.
   PubMed     Text format     Abstract available
   
   

   
   BJU Int

5. QU LG, Wardan H, Davis ID, Iddawela M, et al
   Circulating Estrogen Receptor Mutations and Splice Variants in Advanced Prostate Cancer.
   BJU Int. 2019 May 15. doi: 10.1111/bju.14797.
   PubMed     Text format     Abstract available
   
   
6. SAAD M, Alip A, Lim J, Abdullah MM, et al
   Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
   BJU Int. 2019 May 11. doi: 10.1111/bju.14807.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

7. FRANTZI M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, et al
   CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.
   Br J Cancer. 2019 May 16. pii: 10.1038/s41416-019-0472.
   PubMed     Text format     Abstract available
   
   

   
   Cancer

8. VICTORSON D, Schalet BD, Kundu S, Helfand BT, et al
   Establishing a common metric for self-reported anxiety in patients with prostate cancer: Linking the Memorial Anxiety Scale for Prostate Cancer with PROMIS Anxiety.
   Cancer. 2019 May 15. doi: 10.1002/cncr.32189.
   PubMed     Text format     Abstract available
   
   

   
   Eur J Radiol

9. MIN X, Li M, Dong D, Feng Z, et al
   Multi-parametric MRI-based radiomics signature for discriminating between clinically significant and insignificant prostate cancer: Cross-validation of a machine learning method.
   Eur J Radiol. 2019;115:16-21.
   PubMed     Text format     Abstract available
   
   

   
   Eur Urol

10. GANDAGLIA G, Albers P, Abrahamsson PA, Briganti A, et al
    Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Eur Urol. 2019 May 12. pii: S0302-2838(19)30347.
    PubMed     Text format     Abstract available
    
    
11. LIANG J, Beckta JM, Bindra RS
    Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. In press. h
    Eur Urol. 2019 May 9. pii: S0302-2838(19)30358.
    PubMed     Text format    
    
    

    
    Int J Cancer

12. MITRAN B, Rinne SS, Konijnenberg MW, Maina T, et al
    Trastuzumab co-treatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist (177) Lu-DOTAGA-PEG2 -RM26.
    Int J Cancer. 2019 May 11. doi: 10.1002/ijc.32401.
    PubMed     Text format     Abstract available
    
    
13. 
    Retraction: Festuccia, C., Gravina, G. L., Angelucci, A., Millimaggi, D., Muzi, P., Vicentini, C. and Bologna, M. (2005), Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonster
    Int J Cancer. 2019;145:E12.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

14. ZHANG P, Yang X, Wang L, Zhang D, et al
    Overexpressing miR335 inhibits DU145 cell proliferation by targeting early growth response 3 in prostate cancer.
    Int J Oncol. 2019;54:1981-1994.
    PubMed     Text format     Abstract available
    
    
15. PAN D, Jia Z, Li W, Dou Z, et al
    The targeting of MTDH by miR1455p or miR1453p is associated with prognosis and regulates the growth and metastasis of prostate cancer cells.
    Int J Oncol. 2019;54:1955-1968.
    PubMed     Text format     Abstract available
    
    
16. GAO Y, Li L, Li T, Ma L, et al
    Simvastatin delays castrationresistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin1.
    Int J Oncol. 2019;54:2054-2068.
    PubMed     Text format     Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

17. FERNANDES CD, Simoes R, Ghobadi G, Heijmink SW, et al
    Multi-parametric MRI tumor probability model for the detection of locally recurrent prostate cancer after radiotherapy: pathological validation and comparison with manual tumor delineations.
    Int J Radiat Oncol Biol Phys. 2019 May 11. pii: S0360-3016(19)30703.
    PubMed     Text format     Abstract available
    
    

    
    Int J Urol

18. YUASA T
    Editorial Comment to Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Int J Urol. 2019 May 12. doi: 10.1111/iju.14018.
    PubMed     Text format    
    
    
19. BIANCHI L, Schiavina R, Borghesi M, Ceci F, et al
    How does (68) Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?
    Int J Urol. 2019 May 13. doi: 10.1111/iju.14012.
    PubMed     Text format     Abstract available
    
    
20. AFFERI L, Baumeister P, Mordasini L, Mattei A, et al
    Editorial Comment to How does (68) Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?
    Int J Urol. 2019 May 13. doi: 10.1111/iju.14025.
    PubMed     Text format    
    
    

    
    J Magn Reson Imaging

21. BARRETT T, Riemer F, McLean MA, Kaggie JD, et al
    Molecular imaging of the prostate: Comparing total sodium concentration quantification in prostate cancer and normal tissue using dedicated (13) C and (23) Na endorectal coils.
    J Magn Reson Imaging. 2019 May 13. doi: 10.1002/jmri.26788.
    PubMed     Text format     Abstract available
    
    

    
    J Natl Cancer Inst

22. KERNS SL, Fachal L, Dorling L, Barnett GC, et al
    Radiogenomics Consortium Genome-Wide Association Study Meta-analysis of Late Toxicity after Prostate Cancer Radiotherapy.
    J Natl Cancer Inst. 2019 May 16. pii: 5490201. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Urol

23. MARTIN C, Haaland B, Tward AE, Dechet C, et al
    Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making.
    J Urol. 2019;201:751-758.
    PubMed     Text format     Abstract available
    
    
24. CARTER HB
    Editorial Comment.
    J Urol. 2019;201:922.
    PubMed     Text format    
    
    
25. ZUNIGA KB, Zhao S, Kenfield SA, Cedars B, et al
    Trends in complementary and alternative medicine use among patients with prostate cancer.
    J Urol. 2019 May 15:101097JU0000000000000336. doi: 10.1097/JU.0000000000000336.
    PubMed     Text format     Abstract available
    
    
26. CARROLL P, Schmidt B
    Editorial Comment.
    J Urol. 2019;201:820.
    PubMed     Text format    
    
    

    
    N Engl J Med

27. GOODMAN PJ, Tangen CM, Thompson IM Jr
    More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. Reply.
    N Engl J Med. 2019;380:e38.
    PubMed     Text format    
    
    
28. GARNICK MB
    More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
    N Engl J Med. 2019;380:e38.
    PubMed     Text format    
    
    
29. STAPFF MP, Palm S
    More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.
    N Engl J Med. 2019;380:e38.
    PubMed     Text format    
    
    

    
    Nat Rev Urol

30. GOLDENBERG SL, Nir G, Salcudean SE
    A new era: artificial intelligence and machine learning in prostate cancer.
    Nat Rev Urol. 2019 May 15. pii: 10.1038/s41585-019-0193.
    PubMed     Text format     Abstract available
    
    

    
    Oncology (Williston Park)

31. GUPTA A, Pugh TJ, Lam E, Sheridan AD, et al
    The Role of Primary Tumor Treatment and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer.
    Oncology (Williston Park). 2019;33.
    PubMed     Text format    
    
    

    
    PLoS One

32. REDDY V, Iskander A, Hwang C, Divine G, et al
    Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death.
    PLoS One. 2019;14:e0211090.
    PubMed     Text format     Abstract available
    
    
33. HAMMES J, Hohberg M, Tager P, Wild M, et al
    Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT.
    PLoS One. 2018;13:e0209613.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

34. ZHENG Y, Comaills V, Burr R, Boulay G, et al
    COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis.
    Proc Natl Acad Sci U S A. 2019;116:5223-5232.
    PubMed     Text format     Abstract available
    
    
35. STOPSACK KH, Whittaker CA, Gerke TA, Loda M, et al
    Aneuploidy drives lethal progression in prostate cancer.
    Proc Natl Acad Sci U S A. 2019 May 13. pii: 1902645116.
    PubMed     Text format     Abstract available
    
    

    
    Prostate

36. HERNANDEZ-LLODRA S, Segales L, Safont A, Juanpere N, et al
    SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
    Prostate. 2019 May 15. doi: 10.1002/pros.23830.
    PubMed     Text format     Abstract available
    
    
37. RAMAKRISHNAN S, Steck SE, Arab L, Zhang H, et al
    Association among plasma 1,25(OH)2 D, ratio of 1,25(OH)2 D to 25(OH)D, and prostate cancer aggressiveness.
    Prostate. 2019 May 11. doi: 10.1002/pros.23824.
    PubMed     Text format     Abstract available
    
    
38. BLACKBURN J, Vecchiarelli S, Heyer EE, Patrick SM, et al
    TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: A focus on Africa.
    Prostate. 2019 May 15. doi: 10.1002/pros.23823.
    PubMed     Text format     Abstract available
    
    

    
    Urology

39. KAYE DR, Ye Z, Li J, Herrel LA, et al
    The Stability of Physician-Specific Episode Costs for Urologic Cancer Surgery: Implications for Urologists Under the Merit-Based Incentive Program.
    Urology. 2019;123:114-119.
    PubMed     Text format     Abstract available
    
    
40. LI R, Zhang M, Duplisea JJ, Troncoso P, et al
    Detection and Treatment of Primary Prostatic Melanoma.
    Urology. 2019;123:16-19.
    PubMed     Text format     Abstract available
    
    
41. RAMIREZ-BACKHAUS M, Bertolo R, Mamber A, Ferrer AG, et al
    Live Surgery for Laparoscopic Radical Prostatectomy-Does it Worsen the Outcomes? A Single-center Experience.
    Urology. 2019;123:133-139.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: